Evoke Wealth’s Tvardi Therapeutics TVRD Stock Holding History

Evoke Wealth’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-3	Closed	-$1K	–	1084
2020 Q3	$1K	Hold	3	–	–	﹤0.01%	995
2020 Q2	$2K	Buy	+3	New	+$1.66K	﹤0.01%	913

Other funds holding TVRD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Evoke Wealth's TVRD Position: Q4 2020 in Review

Evoke Wealth sold out of Tvardi Therapeutics (TVRD) in Q4 2020, closing a stake of 3 shares — an estimated $1K sold.

Evoke Wealth first reported a position in TVRD in Q2 2020 and held it in 2 quarters. The position peaked at $2K in Q2 2020. 156 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

Evoke Wealth reported no remaining Tvardi Therapeutics position as of Q4 2020 after selling out during the quarter.
Evoke Wealth sold 3 Tvardi Therapeutics shares in Q4 2020, an estimated $1K.
Evoke Wealth first reported a position in Tvardi Therapeutics in Q2 2020 and held it in 2 quarters.
Evoke Wealth's Tvardi Therapeutics position peaked at $2K in Q2 2020.
156 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Evoke Wealth's 13F filing for Q4 2020, filed 12 Feb 2021.